A number of other research firms have also recently commented on MEDP. Credit Suisse Group AG assumed coverage on shares of Medpace Holdings in a research note on Tuesday, September 6th. They set an outperform rating and a $35.00 price target for the company. William Blair reaffirmed an outperform rating on shares of Medpace Holdings in a research note on Tuesday, September 6th. Robert W. Baird assumed coverage on shares of Medpace Holdings in a research note on Tuesday, September 6th. They set a neutral rating and a $35.00 price target for the company. Finally, Wells Fargo & Co. started coverage on shares of Medpace Holdings in a research note on Tuesday, September 6th. They set an outperform rating for the company. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Medpace Holdings presently has a consensus rating of Buy and a consensus price target of $34.17.
Medpace Holdings (NASDAQ:MEDP) opened at 30.21 on Tuesday. Medpace Holdings has a 52 week low of $26.51 and a 52 week high of $31.35. The company’s market cap is $986.11 million. The firm’s 50 day moving average is $29.46 and its 200-day moving average is $29.34.
In related news, CEO August J. Troendle acquired 869,565 shares of the stock in a transaction on Tuesday, August 16th. The stock was bought at an average cost of $23.00 per share, with a total value of $19,999,995.00. Following the transaction, the chief executive officer now directly owns 1,221,416 shares in the company, valued at $28,092,568. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Susan E. Burwig acquired 19,211 shares of the stock in a transaction on Wednesday, August 17th. The stock was bought at an average cost of $29.21 per share, with a total value of $561,153.31. Following the completion of the transaction, the insider now owns 1,211 shares in the company, valued at $35,373.31. The disclosure for this purchase can be found here.
About Medpace Holdings
Medpace Holdings, Inc is a holding company. The Company operates as a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company is focused on conducting clinical trials across therapeutic areas, with focus in cardiology, metabolic disease, oncology, endocrinology, central nervous system (CNS), and Anti-Viral and Anti-Infective (AVAI).
Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.